Status:
COMPLETED
Phospholipase A2 Receptor (PLA2R1) Autoantibodies in Membranous Nephropathy in Kidney Transplantation
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Kidney Transplantation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The Membranous nephropathy (GEM)idiopatic is the most frequent cause of syndrome néphrotique at the adult and represent approximately 2 % of the causes of terminal chronic renal insufficiency. A etiol...
Eligibility Criteria
Inclusion
- Patients of 18 or more years old,
- Presenting one of the following three profiles:
- Group 1: patients whose renal disease of origin is a GEM, and
- or 1a: that must receive a renal transplantation, or transplanted for less than three months and having a day serum of the transplantation available on the laboratory of immunology or virology,
- or 1b: transplanted for more than three months, not having done it again a GEM yet, and having a day serum of the transplantation available on the laboratory of immunology or virology.
- Group 2: transplanted patients whose renal disease of origin is a GEM, having done it again a GEM on their renal transplant, and having an available serum the day of the transplantation and of the diagnosis of second offense of GEM in the laboratory of immunology or virology.
- Group 3: transplanted patients, and having developed a GEM of novo, and having an available serum the day of the transplantation and of the diagnosis of GEM of novo in the laboratory of immunology or virology.
Exclusion
- vulnerable person
Key Trial Info
Start Date :
January 10 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 3 2018
Estimated Enrollment :
137 Patients enrolled
Trial Details
Trial ID
NCT01897961
Start Date
January 10 2012
End Date
March 3 2018
Last Update
February 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nice
Nice, France, 06000